<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152666">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112566</url>
  </required_header>
  <id_info>
    <org_study_id>BRC-CS-2010-03</org_study_id>
    <nct_id>NCT01112566</nct_id>
  </id_info>
  <brief_title>EASE MITRAL Expertise-based Assessment Study on Clinical Efficacy of Profile 3D in MITRAL Valve Annuloplasty</brief_title>
  <official_title>EASE MITRAL Expertise-based Assessment Study on Clinical Efficacy of Profile 3D in MITRAL Valve Annuloplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to identify the patients suffering from a mitral valve condition
      who benefit from the implantation of a Profile 3D annuloplasty ring in terms of acute and
      long-term relief of mitral valve regurgitation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Actual">November 26, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify the patient population for which a Profile 3D Annuloplasty Ring is chosen to repair the mitral valve insufficiency.</measure>
    <time_frame>screening</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the percentage of patients that are chronically relieved from mitral valve dysfunction</measure>
    <time_frame>6-12 months follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the level of mitral valve regurgitation in patients</measure>
    <time_frame>6-12 months post-surgery</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">152</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population includes all patients suffering from mitral valve disease,
        indicated for a mitral valve repair procedure, either as a stand-alone procedure or
        concomitant to a coronary artery bypass grafting, an aortic replacement or tricuspid valve
        repair and/or the treatment of atrial fibrillation, and for which the surgeon considers
        the implantation of a Profile 3D annuloplasty product most appropriate to reconstruct the
        regurgitant valve.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indicated for a surgical repair for moderate to severe mitral valve regurgitation at
             rest (level 2 or higher);

          -  Willing to return to the hospital where the implantation originally occurred as part
             of the standard practice of care

        Exclusion Criteria:

          -  Heavily calcified valves

          -  Valvular retraction with severely reduced mobility

          -  Active bacterial endocarditis

          -  Already participating in another investigational device study, possibly leading to
             bias and jeopardizing the scientific appropriate assessment of the study endpoints;

          -  Life expectancy of less than one year;

          -  Pregnant or desire to be pregnant within 12 months of the study treatment;

          -  Under 18 years or over 85 years of age.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>London Health Sciences Centre, University Hospital</name>
      <address>
        <city>London Ontario</city>
        <zip>ON N6G 2V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Ceske Budejovice A.S.</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>37001</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut - Leveque - CHU Pessac Cedex Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôpital Nord Laennec</name>
      <address>
        <city>Nantes</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SANA Herzchirurgie Stuttgart GmbH</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Saudi Arabia</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.medtronic.com</url>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>April 27, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
